Ask AI

Capsule Summaries


Share

Program Content

Activities

EMBRACE: N6LS Safety and Tolerability
EMBRACE: Safety and Tolerability of VH3810109 (N6LS) in People With Virologically Suppressed HIV
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 22, 2025

CLARITY
CLARITY: Comparison of Long-Acting Injectable Antiretrovirals in Healthy Adults Without HIV
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 22, 2025

PURPOSE 2 Subanalysis
PURPOSE 2 Subanalysis: Annual Persistence on Twice-Yearly LEN vs Daily FTC/TDF for PrEP Among Cisgender Men and Gender-Diverse People
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 22, 2025

Weekly Oral ISL and LEN
Once-Weekly Oral ISL + LEN in People Living With Virologically Suppressed HIV: Wk 96 Results
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 23, 2025

ACTG A5391 DO IT Metabolic Analysis
ACTG A5391/DO-IT: Metabolic Parameters and Body Composition After Switch to DOR ± TDF vs Continuing INSTI + TAF/FTC 
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 23, 2025

Weight Gain in P052 Study
P052 (MK-8591A-052) Phase III Trial of Switch From BIC/FTC/TAF to Doravirine/Islatravir: Impact on Weight and Body Composition at Wk 48
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 23, 2025

EMPOWER
EMPOWER: Treatment Satisfaction of People Living With Virologically Suppressed HIV on LA ART Who Switched to Daily Oral BIC/FTC/TAF
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 23, 2025

Lenacapavir Teropavimab Zinlirvimab
Phase II Study of Lenacapavir, Teropavimab, and Zinlirvimab in People Living With Virologically Suppressed HIV: Wk 52 Results
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 23, 2025

PREFER-LA
PREFER-LA: Switch to LA CAB + RPV in People Living With HIV and Previous Adherence Challenges
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 24, 2025

LEN PrEP in Substance Use
PURPOSE 2: Adherence to and Safety of Lenacapavir for PrEP Among People Who Use Substances
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 24, 2025

MORE At Home HIV Care
MORE Program: At-Home LA CAB + RPV Injections for People Living With HIV Experiencing Adherence Challenges
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 27, 2025

PURPOSE 2 LEN and GAHT
PURPOSE 2: Pharmacokinetic Effects of Lenacapavir on Gender-Affirming Hormone Therapy in Gender-Diverse People 
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 27, 2025

PREFER LA
PREFER-LA: Real-world Efficacy of Switch to LA CAB + RPV in People Living With HIV and Adherence Challenges 
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 28, 2025

LEN Real World Adherence
Real-world Lenacapavir Efficacy and Adherence: Long-term Follow-up From the OPERA Cohort
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 28, 2025

Zoster Vaccination in HIV
Impact of Zoster Infection and Vaccination on Cardiovascular Risk and Mortality in People Living With HIV
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 28, 2025

MK-8591A-054
MK-8591A-054: Interim Analysis of Safety and Efficacy of Reduced-Dose DOR/ISL in People Living With Virologically Suppressed HIV
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 29, 2025

LEN in HTE HIV
Real-world Lenacapavir in Heavily Treatment–Experienced People Living With HIV: Virologic Outcomes, Pill Burden, and Number of Total and Active Agents
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 29, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare